Subtype-Specific FBXW7 Mutation and MYCN Copy Number Gain in Wilms' Tumor

Richard D. Williams¹, Reem Al-Saadi¹, Tasnim Chagtai¹, Sergey Popov¹, Boo Messahel¹, Neil Sebire², Manfred Gessler³, Jenny Wegert³, Norbert Graf², Ivo Leuschner⁵, Mike Hubank², Chris Jones¹, Gordan Vujanic⁶, Kathy Pritchard-Jones¹, Children's Cancer and Leukaemia Group, and SIOP Wilms' Tumour Biology Group

Abstract

Purpose: Wilms' tumor (WT), the most common pediatric renal malignancy, is associated with mutations in several well-characterized genes, most notably WT1, CTNNB1, WTX, and TP53. However, the majority of cases do not harbor mutations in these genes. We hypothesized that additional drivers of tumor behavior would be contained within areas of consistent genomic copy number change, especially those associated with the WT risk groups defined by the International Society of Paediatric Oncology (SIOP).

Experimental Design: We analyzed high-resolution (Affymetrix 250K single nucleotide polymorphism array) genomic copy number profiles of over 100 tumors from selected risk groups treated under the SIOP protocols, further characterizing genes of interest by sequencing, Multiplex Ligation-dependent Probe Amplification, or fluorescence in situ hybridization.

Results: We identified FBXW7, an E3 ubiquitin ligase component, as a novel Wilms' tumor gene, mutated or deleted in ~4% of tumors examined. Strikingly, 3 of 14 (21%) of tumors with epithelial type histology after neoadjuvant chemotherapy had FBXW7 aberrations, whereas a fourth WT patient had germline mutations in both FBXW7 and WT1. We also showed that MYCN copy number gain, detected in 9 of 104 (8.7%) of cases, is relatively common in WT and significantly more so in tumors of the high risk diffuse anaplastic subtype (6 of 19, 32%).

Conclusions: Because MYCN is itself a target of FBXW7-mediated ubiquitination and degradation, these results suggest that a common pathway is dysregulated by different mechanisms in various WT subtypes. Emerging therapies that target MYCN, which is amplified in several other pediatric cancers, may therefore be of value in high risk Wilms' tumor. Clin Cancer Res; 16(7); 2036–45. ©2010 AACR.

Wilm's tumor (WT) is the most common pediatric renal malignancy. Somatic or germline mutations in several genes have been identified in WT over the last two decades. WT1, which encodes a zinc finger nucleic acid–binding protein with multiple roles in gene regulation and development, is mutated or deleted in ~15% of WT (reviewed in ref. 1). Gain-of-function mutations in WNT signaling component CTNNB1 (β catenin) are found in a similar proportion of tumors (2), usually in combination with WT1 mutations (3–6). Mutation or loss of a third gene, WTX (FAM123B), occurs in up to 30% of sporadic WTs (7), independently of other aberrations (8). Epigenetic abnormalities at 11p15, affecting expression of H19 and IGF2, are found in significant numbers of WTs, including those cases associated with Beckwith-Wiedemann syndrome (9, 10). Increased WT incidence has also been linked with several other rare developmental disorders, some of which have defined genetic lesions that are occasionally found in sporadic tumors (11). TP53 mutations are largely restricted to the relatively uncommon anaplastic WT subtype (12). Taken together, however, somatic mutations in known WT genes account for fewer than half of cases, and identifying the underlying drivers of the remainder is a problem of significant biological and therapeutic interest.

We have analyzed copy number aberrations in samples from the International Society of Paediatric Oncology (SIOP) 2001 WT clinical trial and study, aiming to identify novel changes associated with particular histologic
subtypes and clinical risk groups, or affecting loci of general relevance to WT. Patients in this study typically receive a short period (4–6 weeks) of neoadjuvant chemotherapy before surgery, with risk groups defined by histology at nephrectomy, a direct measure of in vivo chemosensitivity (13). Our analysis has now detected recurrent focal aberrations targeting two genes whose dysregulation is pathogenic in other cancers. FBXW7, a ubiquitin ligase component that acts as a tumor suppressor, is frequently mutated in cholangiocarcinoma and T-cell acute lymphoblastic leukemia, and somewhat less commonly in a range of other malignancies (14). Here, we identify FBXW7 as a novel Wilms’ tumor gene, which is deleted or mutated in ~4% of the tumors examined and in which the aberrations thus far detected are restricted to tumors with intermediate risk histologies. MYCN, a MYC family transcription factor and proto-oncogene, is amplified in neuroblastoma (15), in which it is an established biomarker for treatment stratification (reviewed in refs. 16, 17), and in several other embryonal pediatric tumors. We show that genomic gain or amplification of MYCN, previously described in only a few individual WT cases, is relatively common, especially in tumors of intermediate (high risk) histology. FBXW7 mediates degradation of MYCN, whose overexpression at the protein level is linked with poor outcome in WT. Hence, these results implicate a common oncogenic pathway that could be targeted by new therapeutic agents, such as those being developed to inhibit MYCN function in neuroblastoma. Because anaplastic WT, in its metastatic or recurrent form, remains largely intractable to current therapies, the identification of a potential target associated with this histology is of high clinical relevance.

Materials and Methods

Frozen tumor material obtained from postchemotherapy nephrectomy specimens was collected from 104 patients treated in the SIOP WT 2001 clinical trial at UK (n = 85) and German (n = 19) centers. Because the availability of suitable frozen material that meets quality control standards for array analysis depends on multiple factors, including the pathology practices at each clinical center, samples were not consecutive within the trial or by histologic risk group. A pragmatic approach to sample selection was taken, based on ensuring that approximately equal numbers of tumors in each of the major histologic groups of the SIOP 2001 classification (13) were represented (see Supplementary Data), resulting in a sample series enriched in some of the rarer subtypes. These samples were supplemented by five tumors from other sources in the FBXW7 sequencing analysis only. Patient consent and ethical approval were obtained for the use of all samples. A section from each sample was reviewed by a pediatric pathologist to confirm tumor content without significant contamination by normal tissue. DNA was extracted from frozen material by standard protocols and was profiled at UCL Genomics on the Affymetrix Human Mapping 250K Nsp single nucleotide polymorphism (SNP) array according to the manufacturer’s instructions. Data were processed for copy number estimation using the Affymetrix CNAT 4.0 package, with quantile normalization and a 0.1-Mb Gaussian smoothing window. Normal control data from the 30 Caucasian CEPH trio mothers (http://www.cephb.fr) was obtained from the HapMap consortium (http://www.hapmap.org/) and was used as the baseline for copy number comparisons. The copy number data set was processed and annotated for downstream analysis with custom Perl scripts (Available from http://www.icr.ac.uk/research/research_sections/paediatric_oncology/) and visualized in CGH Explorer (ref. 18; http://www.ifi.uio.no/bioinf/Projects/CGHEXplorer). Data were processed for inferred loss of heterozygosity analysis with dChip (ref. 19; http://biosun1.harvard.edu/complab/dchip/).

The FBXW7, WT1, and WTX coding sequences, and the CTNNB1 exon 3 sequence were amplified from tumor samples by standard methods (see Supplementary Data for primers). Unidirectional sequencing using one primer from each pair and the Applied Biosystems BigDye system was used for initial mutation detection; all candidate mutations were confirmed by bidirectional sequencing.

The Kreatech Poseidon MYCN (2p24) & LAF (2q11) fluorescence in situ hybridization probe set (Kreatech Diagnostics) was used to detect MYCN copy number with reference to the LAF locus (control) according to the manufacturer’s instructions. The P252-NB Multiplex Ligation–dependent Probe Amplification (MLPA) kit (MRCL Holland) was used to measure MYCN copy number by the NHS Northern Genetics Service, Newcastle upon Tyne.

For detailed examination of histology, formalin-fixed, paraffin-embedded tissue sections were prepared and stained with H&E by standard methods.

Results

Deletion of FBXW7 in WT. Analysis of the Affymetrix copy number data (104 tumors) revealed two samples with

Translated Relevance

Wilms’ tumors (WT) treated with preoperative chemotherapy according to SIOP protocols are classified by histologic subtype at resection. This reflects in vivo chemosensitivity and predicts subsequent prognosis but has a poorly defined molecular basis. We have identified FBXW7 as a new Wilms’ tumor gene, mutations of which are associated with epithelial type (intermediate risk) tumor histology, and have shown that copy number gain of MYCN is associated with anaplastic (high risk) histology. FBXW7 mediates degradation of MYCN, whose overexpression at the protein level is linked with poor outcome in WT. Hence, these results implicate a common oncogenic pathway that could be targeted by new therapeutic agents, such as those being developed to inhibit MYCN function in neuroblastoma. Because anaplastic WT, in its metastatic or recurrent form, remains largely intractable to current therapies, the identification of a potential target associated with this histology is of high clinical relevance.

Materials and Methods

Frozen tumor material obtained from postchemotherapy nephrectomy specimens was collected from 104 patients treated in the SIOP WT 2001 clinical trial at UK (n = 85) and German (n = 19) centers. Because the availability of suitable frozen material that meets quality control standards for array analysis depends on multiple factors, including the pathology practices at each clinical center, samples were not consecutive within the trial or by histologic risk group. A pragmatic approach to sample selection was taken, based on ensuring that approximately equal numbers of tumors in each of the major histologic groups of the SIOP 2001 classification (13) were represented (see Supplementary Data), resulting in a sample series enriched in some of the rarer subtypes. These samples were supplemented by five tumors from other sources in the FBXW7 sequencing analysis only. Patient consent and ethical approval were obtained for the use of all samples. A section from each sample was reviewed by a pediatric pathologist to confirm tumor content without significant contamination by normal tissue. DNA was extracted from frozen material by standard protocols and was profiled at UCL Genomics on the Affymetrix Human Mapping 250K Nsp single nucleotide polymorphism (SNP) array according to the manufacturer’s instructions. Data were processed for copy number estimation using the Affymetrix CNAT 4.0 package, with quantile normalization and a 0.1-Mb Gaussian smoothing window. Normal control data from the 30 Caucasian CEPH trio mothers (http://www.cephb.fr) was obtained from the HapMap consortium (http://www.hapmap.org/) and was used as the baseline for copy number comparisons. The copy number data set was processed and annotated for downstream analysis with custom Perl scripts (Available from http://www.icr.ac.uk/research/research_sections/paediatric_oncology/) and visualized in CGH Explorer (ref. 18; http://www.ifi.uio.no/bioinf/Projects/CGHEXplorer). Data were processed for inferred loss of heterozygosity analysis with dChip (ref. 19; http://biosun1.harvard.edu/complab/dchip/).

The FBXW7, WT1, and WTX coding sequences, and the CTNNB1 exon 3 sequence were amplified from tumor samples by standard methods (see Supplementary Data for primers). Unidirectional sequencing using one primer from each pair and the Applied Biosystems BigDye system was used for initial mutation detection; all candidate mutations were confirmed by bidirectional sequencing.

The Kreatech Poseidon MYCN (2p24) & LAF (2q11) fluorescence in situ hybridization probe set (Kreatech Diagnostics) was used to detect MYCN copy number with reference to the LAF locus (control) according to the manufacturer’s instructions. The P252-NB Multiplex Ligation–dependent Probe Amplification (MLPA) kit (MRCL Holland) was used to measure MYCN copy number by the NHS Northern Genetics Service, Newcastle upon Tyne.

For detailed examination of histology, formalin-fixed, paraffin-embedded tissue sections were prepared and stained with H&E by standard methods.

Results

Deletion of FBXW7 in WT. Analysis of the Affymetrix copy number data (104 tumors) revealed two samples with
Fig. 1. FBXW7 mutations in WT. A, chromosome 4 copy number profiles (log2 scale) for WT samples RMH-2990 and RMH-2594. Arrow, position of the FBXW7 gene; red, FBXW7-specific probe positions. B, extent of the 4q31.3 deletions relative to NCBI RefSeq genes and Affymetrix 250K SNP probe positions (48). C, sequence chromatograms for FBXW7 mutations detected in WT samples RMH-1549 and RMH-4714; FISH, fluorescence in situ hybridization.
focal and apparently homozygous deletions on 4q31.1 (Fig. 1A). In both samples, loss of 1p and gain of 1q were also observed. In one case (RMH-2594) the 4q31.1 deletion was the sole additional major abnormality detected in the genome at the resolution of the 250K Nsp array. In the second (RMH-2990), three further less focal aberrations consistent with heterozygous deletions were detected on chromosome 4, but no other major genomic changes were apparent. The focal 4q31.1 deletions in both samples contained the complete sequence of the FBXW7 gene. Although the focal aberration in RMH-2990 encompassed seven other RefSeq genes (Fig. 1B), the more limited deletion in RMH-2594 (Fig. 1B) included only two complete genes (TMEM154 and TIGD4) and part of a third (ARFIPI) in addition to FBXW7. As FBXW7 is a well-characterized tumor suppressor gene (14), whereas TMEM154, TIGD4, and ARFIPI have no established roles in cancer, we prioritized FBXW7 for further evaluation.

**Point mutation of FBXW7 in WT.** To determine if FBXW7 in WT is subject to point mutations or other abnormalities below the resolution of the Affymetrix 250K array, we sequenced the coding sequence of this gene in 88 samples, 77 of which had also been analyzed on the array. All sequences were complete except in seven cases, in which data were not obtained for 1 or 2 of the 13 coding exons (see Supplementary Data). Two further mutations were detected (Fig. 1C), in both cases in tumors with neutral copy number profiles (no major changes detected; data not shown). In RMH-1549, a heterozygous G to A transition (c.1436G>A, relative to the α isoform) results in the substitution of Arg-479 with Gln (p.R479Q). Arg-479 is the second most common mutual hotspot in FBXW7 across a range of tumor types and retention of the wild-type allele is typical of primary tumors harboring such mutations (14). In RMH-4714, a heterozygous three base insertion (c.45_46insCTT; Fig. 1C) introduces a proline at residue 16 (T16G16insP) of the predominant FBXW7 α isoform, a mutation previously observed in prostate cancer (14).

Sequencing FBXW7 in matched peripheral blood DNA from the patients with tumors RMH-1549 and RMH-4714 revealed that the mutation in RMH-1549 was confined to the tumor, whereas the proline insertion in RMH-4714 was also present in the germline. It is also notable that both tumors with FBXW7 deletions detected on the array (RMH-2594 and RMH-2990) and the sample with the Arg-479 hotspot mutation (RMH-1549) were of the relatively uncommon epithelial subtype, found in only 10% of the WTs classified according to the SIOP criteria for tumors resected after chemotherapy (13). This subtype is considered “intermediate risk.” Because only 14 of 77 of the jointly arrayed and sequenced samples were epithelial type, this result suggests that FBXW7 mutations exhibit specificity to this subtype ($P = 0.018$, Fisher’s exact test). The germline proline insertion (RMH-4714) was in a patient with stromal type histology, an intermediate risk subtype frequently associated with WT1 and CTNNB1 mutations (20–23). No FBXW7 aberrations were detected in tumors with high-risk histologies or in the mixed or regressive intermediate risk subtypes.

**MYCN gain in WT.** Nine samples had evidence of MYCN gain (examples in Fig. 2A, extent of gain in Fig. 2B). In six of these tumors, this was a focal (typically ~0.25 Mb) low-copy number event (typically consistent with single copy gain). In two cases (RMH-2969 and RMH-4718) a somewhat higher level, but still focal, gain was observed. In the remaining sample (RMH-2967), a broader, high-level amplification (>10 copies) was detected and confirmed by fluorescence in situ hybridization in 90 of 94 assessed nuclei of cells from a frozen tumor touch preparation (Fig. 2C). The level of gain in eight of the nine samples was assessed by MLPA, which confirmed the array results (Fig. 2D). Six of the nine samples, including those with the highest levels of gain, were of the high-risk diffuse anaplastic subtype. One other tumor (RMH-3725) was also classed as a high-risk histology (blastoskeletal type). The remaining samples (RMH-205, RMH-4644) were of intermediate risk mixed histology. Because only 19 of 104 of the tumors profiled were of the diffuse anaplastic subtype, and 6 of these (32%) had MYCN gain, these results indicate a significant association between anaplasia and this aberration ($P = 0.001$, Fisher’s exact test).

**Status of known WT genes in samples with FBXW7 or MYCN aberrations.** To determine if other known WT genes are mutated in the samples with FBXW7 or MYCN aberrations, we examined the coding sequences of WT1 and WTX, and the exon 3 sequence of CTNNB1, in all four samples with FBXW7 deletion or mutation and in eight of the nine samples with MYCN gain; sequence data were not available for RMH-3725 (see Supplementary Data). The SNP data for all 13 samples of interest were also examined for inferred loss of heterozygosity (tumor only, without reference to matched normal; ref. 19) at 11p13 and 11p15.5.

RMH-4714, the sample with a germline FBXW7 mutation, was found to have mutations in both WT1 and CTNNB1; no other WT1, CTNNB1, or WTX mutations were detected in this sample series. Two heterozygous WT1 mutations were found in RMH-4714: c.948_949insG, a single base insertion that introduces a frameshift in exon 2, and c.1568C>T (p.R390X, relative to the longest WT1 isoform translated from the ATG initiation codon at c.401), a single base substitution that introduces a stop codon in exon 9, terminating the protein in its third zinc finger and eliminating the fourth and final zinc finger. The c.1568C>T (p.R390X) mutation was also found in the germline, but c.948_949insG was confined to the tumor, potentially representing a second hit in the other allele (allelic specificity was not determined). Two CTNNB1 nucleotides were heterozygously mutated in RMH-4714 (tumor only), substituting adjacent amino acid residues: c.398C>G (p.P44A) and c.401T>C (p.S45P). Ser-45 is a mutational hotspot in WT and other tumors, while simultaneous P44A and S45P substitutions have
been reported in WT and hepatocellular carcinoma (24, 25). RMH-1549 had evidence of loss of heterozygosity at 11p15.5, but not 11p13; none of the other 12 samples had inferred loss of heterozygosity in either of these regions.

Because the patient with tumor RMH-4714 carried germline mutations in both \textit{FBXW7} and \textit{WT1}, we reviewed the clinical data for this case. Although not diagnosed with any known WT-associated syndrome or genitourinary abnormalities, the patient (a phenotypic and genetic XX female) had a younger than average age at diagnosis (14 months) and presented with bilateral renal masses, both features suggestive of genetic predisposition. The larger mass (11-cm diameter) proved to be a WT (RMH-4714). The smaller mass (2-cm diameter) in the contralateral kidney showed pronounced cystic change after chemotherapy; hence, it could not be confirmed whether this may have been a WT precursor lesion (nephrogenic rest).

\textbf{Histology of samples with \textit{FBXW7} or \textit{MYCN} aberrations.} Because \textit{FBXW7} mutations were associated with epithelial histology and \textit{MYCN} gain was associated with diffuse anaplasia, we reviewed the pathology reports and (where available) formalin-fixed, paraffin-embedded sections of the UK Children’s Cancer and Leukaemia Group samples with aberrations in either gene to determine if they had specific distinguishing features in addition to those that defined their histologic subtypes (see Supplementary Data). All three samples with \textit{FBXW7} aberrations, but no mutations in other WT genes (RMH-1549, RMH-2594, RMH-2990), had unambiguous epithelial-type histology (e.g., Fig. 3A and B), consisting of 90% to 100% epithelial elements (tubules with a range of differentiation and tubulo-papillary structures). No specific features beyond those normally associated with epithelial-type histology were observed, although RMH-1549, the sample with a mutation at the R479Q hotspot, was more highly differentiated than the other two tumors. RMH-4714, the sample with mutations in \textit{WT1}, \textit{CTNNB1}, and \textit{FBXW7}, was clearly of stromal type histology (~85% stromal elements), although some epithelial elements (~12.5%) were detectable (data not shown). All six tumors with \textit{MYCN} gain and diffuse anaplasia were confirmed to have the characteristic features of anaplastic.
WT, including nuclear enlargement, hyperchromasia, and atypical mitotic figures (Fig. 3C and D). However, the tumor with the highest level of MYCN gain, RMH-2967, also had some areas of rhabdoid-like features, including vesicular nuclei, very prominent nucleoli, and noncohesive cells (Fig. 3C and E). Similar but less prominent features were also evident in three of the remaining five MYCN+ anaplastic WTs (e.g., Fig. 3D and F), but in only one of six UK anaplastic tumors without MYCN gain.

**Discussion**

FBXW7 mutations have not previously been described in WT. However, both point mutations detected here have been observed in other tumors. Arg-479 is a key surface residue in the FBXW7 WD40 repeat III, a component of the β-propeller structure responsible for substrate recognition and a frequent mutational hotspot in multiple tumor types (14). As in our cases, primary tumors with FBXW7 point mutations typically retain the wild-type allele (14). Such heterozygous mutants, in which substrate binding is disrupted while other interactions remain unaffected, are believed to act through haplo-insufficient (26) or dominant-negative (27) mechanisms, and there is direct evidence that R479Q has dominant-negative activity (14).

The T15_G16insP insertion has previously been reported in a single prostate tumor, functionally tested in an embryonic kidney cell line system and found to abolish nuclear localization of the protein and its binding to a known substrate, CCNE1 (Cyclin E; ref. 14). Although the potential dominant-negative activity of the mutant protein was not assessed, it retained the ability to interact with known cofactors, a property consistent with a dominant-negative mechanism of action. The minor β and γ FBXW7 isoforms would not be affected by this insertion, but
neither has the ability to localize to the nucleoplasm and interact with nuclear substrates such as Cyclin E even in the wild-type form and so could not compensate for the mutation. Although T15_G16insP in RMH-4714 is a germline mutation, the functional data, together with the evolutionary conservation of adjacent T15 and G16 residues in most vertebrate species from primates to Fugu (data not shown), strongly suggest a deleterious mutation rather than a rare polymorphism; no insertions at this position have been reported in the National Center for Biotechnology Information (NCBI) dbSNP (build 130).

FBXW7, as an important tumor suppressor gene, is likely to be the primary and potentially sole significant target of the focal homozygous deletions in RMH-2594 and RMH-2990. Similar aberrations are found in T-cell acute lymphoblastic leukemia, a tumor type with a high frequency of FBXW7 point mutations. Our analysis of a published series of 50 T-cell acute lymphoblastic leukemia Affymetrix SNP arrays (NCBI GEO accession GSE9113; ref. 28) revealed four tumors with deletions that included FBXW7, two of which were less focal than those we detected in WT (data not shown), whereas a recent report (29) also describes “discrete” deletions in T-cell acute lymphoblastic leukemia samples at this locus. These results suggest that FBXW7 is targeted by both point mutations and deletions in tumor types in which it is commonly inactivated. No such deletions were detected when we examined publicly available data (GEO accession GSE12494; data not shown; ref. 30) from a large SNP array series derived from neuroblastoma, a tumor in which FBXW7 point mutations have not been

**Fig. 3.** H&E-stained paraffin-embedded sections showing histology of tumors with FBXW7 or MYCN aberrations. A, RMH-2990 (×100 magnification). Epithelial type WT showing poorly and moderately differentiated tubules with some papillary structures. B, RMH-1549 (×100). Epithelial type WT showing highly differentiated tubules. C, RMH-2967 (×100). Diffuse anaplastic WT; arrows, examples of anaplastic cells. D, RMH-2969 (×100). Diffuse anaplastic WT; arrows, examples of anaplastic cells. E, RMH-2967 (×600). Diffuse anaplastic WT with areas of rhabdoid-like histology including prominent nucleoli (arrows). F, RMH-2969 (×600). Diffuse anaplastic WT with areas of rhabdoid-like histology including prominent nucleoli (arrows).
described. Nevertheless, we have not yet ruled out the potential contribution to the tumor phenotype of deletion of the (2–7) immediately adjacent genes in our samples. Other loci on 4q may also be significant in WT. An earlier study (31) has reported loss of heterozygosity on 4q, including a region on 4q24-25 that does not overlap with FBXW7, whereas our own data on multiple genomic array platforms (data not shown) suggest that loss of the entire 4q chromosome arm is relatively frequent in WT.

The potential association between FBXW7 status and histologic subtype we observed is intriguing. All three cases that had FBXW7 aberrations but no mutations in the three other Wilms’ tumor genes examined belonged to the relatively uncommon epithelial subtype and the association between histology and FBXW7 status was significant. It may be relevant that the deletion of a single copy of Fbw7 in a Tp53-hemizygous mouse model results in a shift of the spectrum of observed malignancies toward tumors of epithelial tissues (26). The single tumor with mutations in FBXW7, WT1, and CTNNB1 had stromal-type histology at nephrectomy. Mutations in both WT1 and CTNNB1 (frequently together, as here) have previously been associated with this histology (20–23). We may speculate that in situations in which both the WT1/CTNNB1 and FBXW7 axes are disrupted, the stromal phenotype associated with the former is dominant, overriding any tendency to develop epithelial predominance mediated by the latter. We also note that simultaneous mutation of WT1 and FBXW7 has recently been described in T-cell acute lymphoblastic leukemia (29), although the functional significance of this result is unclear, as the mutation frequencies of the two genes seem to be unrelated. The presence of a germline FBXW7 mutation in the patient with aberrations in all three genes and an abnormality in the contralateral kidney raises the possibility that disruption of FBXW7 may contribute to tumor predisposition. However, because one of the two WT1 mutations in the tumor is also present in the germline, it is not possible to separate the potential contribution of FBXW7 from the known role of WT1.

Earlier studies have reported MYCN gain or amplification in a few individual cases (32–34), although the data were too limited to test for potential associations with subtype. The present study is the first to analyze a WT series including a relatively large number of anaplastic tumors on a high-resolution SNP platform. Our finding of an association between MYCN gain and a high-risk histology in WT is in keeping with emerging evidence that elevated MYCN copy number, originally described in neuroblastoma (15) and used in risk stratification (16, 17), is associated with adverse outcome in other childhood tumors, including rhabdomyosarcoma (35) and medulloblastoma (36, 37). MYCN amplification is also observed in retinoblastoma (38), although existing data do not show a clinical correlation (39). Six of the nine patients in whose WT samples we detected MYCN gain suffered a relapse; five died. Two had intermediate risk mixed histology tumors and four had high-risk histology, including one blastemal type and three anaplastic tumors. Samples from these three anaplastic cases had the highest levels of MYCN gain in the series; the three remaining anaplastic cases with MYCN aberrations had lower levels of gain and did not relapse. On histologic review, the three samples with the highest level of gain were found to have areas containing rhabdoid-like features on a background of diffuse anaplasia. When the detailed histology of all 12 UK anaplastic samples was reviewed, rhabdoid-like features were detected in two additional samples, one (with MYCN gain) from a patient who had not relapsed and the other (without MYCN gain) from a patient who had relapsed and died. A much larger WT series would be required to determine if MYCN gain in combination with anaplasia is associated with a significantly worse outcome than anaplasia alone or if the rhabdoid-like features that seemed more common in the subset of anaplastic tumors with MYCN gain are prognostically significant.

The current data for both genes are largely confined to European nephrectomy samples from patients treated under current SIOP protocols. These tumors have therefore been exposed to preoperative chemotherapy and represent histologic risk groups defined by their in vivo chemosensitivity (13). These groups have no direct equivalents in North American WT series from patients treated under Childhood Oncology Group protocols, who are typically chemo-naïve at resection. However, features such as anaplasia and the predominance of particular cell types (e.g., “epithelial predominance”) are recognized in individual immediate nephrectomy samples from Childhood Oncology Group patients. It would be interesting to conduct a similar analysis in samples drawn from a chemo-naïve series to determine if the apparent subtype specificity we have observed is restricted to classes defined by initial chemotherapy (in which additional mechanisms of selection for subclones carrying the aberrations we detected may operate) or is more broadly applicable to tumor classes characterized by specific histologic features, irrespective of chemotherapy.

Although genomic aberrations in FBXW7 or MYCN are present in only a minority of tumors, other evidence suggests that mechanisms that affect pathways involving these genes are of more general importance in WT. Overexpression of MYCN is a recognized feature of WT (40–42) and its relative expression level has been identified as a significant clinical prognostic marker (43, 44). FBXW7 is a component of an SCF (SKP1/CUL1/FBXW7) E3 ubiquitin ligase complex, which targets several key dominant proto-oncogene products for ubiquitination and subsequent proteasome-mediated degradation (27), with mutations leading to accumulation of its targets. It is therefore suggestive that the protein level of one of these targets, Cyclin E, has been shown to correlate with WT aggressiveness and metastasis (45). Intriguingly, MYCN itself was recently reported to be a direct target of the FBXW7 SCF complex (46). This implies that the loss of FBXW7 or gain of MYCN could have overlapping downstream effects, although the association of these alterations with different histologic
risk groups suggests a more complex picture. MYCN is only one of several known targets of FBXW7, so that disruption of the latter could perturb multiple pathways unaffected by copy number changes in the former. In addition, it is unclear if the dysregulation of MYCN levels by inactivation of FBXW7 would affect MYCN downstream targets to the same degree as direct copy number changes at the MYCN locus. The timing of mutational events and the broader pattern of concomitant genomic changes may also be significant. We detected FBXW7 aberrations in tumors with relatively stable genomes and in one case identified a germline change, features that suggest that disruption of this gene is a relatively early event. In contrast, the majority of MYCN gains were observed in anaplastic tumors with a background of widespread genomic disruption, features suggestive of a relatively late stage of tumor development.

Our results also have implications for the development of future therapeutic strategies. Although WT in general has an excellent response to treatment, anaplastic tumors that are metastatic at diagnosis or that recur remain largely intractable to current therapies. The genomic gain of a biomarker significantly associated with this high-risk histology, and with known oncogenic activity, therefore presents a potentially attractive target for novel treatment agents. Emerging therapies directed at MYCN function in other tumors, particularly neuroblastoma (47), could therefore be of significant clinical value. The link between the FBXW7 and MYCN pathways suggests further possibilities for intervention. For example, the finding that AURKA, itself a known FBXW7 substrate, plays a critical role in sequestering MYCN from FBXW7-mediated degradation (46) highlights one class of interactions that could be targetable. As knowledge of these pathways continues to develop, so should the potential for more effective treatment of the WT patients with the poorest prognosis.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank the families, clinicians, and pathologists who contributed the samples used in this study to the Children's Cancer and Leukaemia Group Tumour Bank, United Kingdom, and the Paediatric Tumour Cell Bank of the Society of Paediatric Oncology and Haematology, Germany. We thank Clare Bedwell and Nick Bown, NHS Northern Genetics Service, Newcastle upon Tyne, for the MLPA analysis.

Grant Support

Cancer Research UK grant C1148/A4614, the Royal Marsden Hospital Children's Fund, and NHS funding to the NIHR Biomedical Research Centre.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 10/29/2009; revised 12/16/2009; accepted 01/07/2010; published OnlineFirst 03/23/2010.

References

Clinical Cancer Research

Subtype-Specific FBXW7 Mutation and MYCN Copy Number Gain in Wilms' Tumor

Richard D. Williams, Reem Al-Saadi, Tasnim Chagtai, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-09-2890

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2010/03/25/1078-0432.CCR-09-2890.DC1

Cited articles
This article cites 47 articles, 12 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/16/7/2036.full.html#ref-list-1

Citing articles
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/16/7/2036.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.